SecBot SecBot

NUVL

Nuvalent, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001861560 Biotech & Drug Discovery
No price
Market cap
$9.8B
Mid cap
Median target
$124.00
range $124.00–124.00
Short interest
715.8K
≈0.9% of shares · −75.4%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · since Jul 15
New fund stakes
14
Q2 2026 13F · 8 exits
Filing reports
18
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Jul 15. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 37 added (14 new), 43 trimmed or exited. Largest new: Pentwater Capital Management $145.1M, Balyasny Asset Management $128.1M.

  • EstimatesFLAT

    Current-quarter EPS estimate −$1.372 → −$1.378 over 90 days. 0 up, 2 down in 30 days.

  • Short sellersCOVERING

    Short interest −75.4% to 715.8K shares. 1.0 days to cover, ≈0.9% of shares.

Who's buying

13F· Q2 2026
14
new positions
8
exits
$553.0M
in new stakes
FundMoveSharesValue
FIL LtdDOUBLED2,946,506$363.9M
GOLDMAN SACHS GROUP INCDOUBLED1,640,833$202.6M
FMR LLCNEAR_EXIT1,417,590$175.1M
BARCLAYS PLCDOUBLED1,268,265$156.6M
RA CAPITAL MANAGEMENT, L.P.TRIM1,246,456$153.9M
Pentwater Capital Management LPNEW1,175,000$145.1M
BALYASNY ASSET MANAGEMENT L.P.NEW1,037,583$128.1M
BANK OF AMERICA CORP /DE/DOUBLED876,830$108.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Jun 2026
Recent actions
DateFirmActionRating
Jun 24, 2026Bernstein
DOWNGRADE
DOWNGRADEMarket Perform
Jun 10, 2026Truist Securities
DOWNGRADE
DOWNGRADEHold
Jun 10, 2026TD Cowen
DOWNGRADE
DOWNGRADEHold
Jun 10, 2026Barclays
DOWNGRADE
DOWNGRADEEqual-Weight
Jun 10, 2026Wedbush
DOWNGRADE
DOWNGRADENeutral
Jun 10, 2026UBS
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$0
open-market buys or sells · since Jul 15
DateInsiderTypeValue
Jul 15, 2026
Srivastava Sapna
Director
Jul 15, 2026
TENDER$638.1K
Jul 15, 2026
Srivastava Sapna
Director
Jul 15, 2026
TO ISSUER3,444 sh
Jul 15, 2026
Srivastava Sapna
Director
Jul 15, 2026
TO ISSUER68,500 sh
Jul 15, 2026
Srivastava Sapna
Director
Jul 15, 2026
TO ISSUER20,000 sh
Jul 15, 2026
Srivastava Sapna
Director
Jul 15, 2026
TO ISSUER15,000 sh
Jul 15, 2026
Srivastava Sapna
Director
Jul 15, 2026
TO ISSUER3,789 sh
Jul 15, 2026
Srivastava Sapna
Director
Jul 15, 2026
TO ISSUER4,147 sh
Jul 15, 2026
Balcom Alexandra
Chief Financial Officer
Jul 15, 2026
AWARD14,350 sh

Earnings setup

Estimates
−$1.38
EPS estimate, this quarter
−0%
estimate change, 90 days
0↑ 2↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.38-$1.48–-$1.13-0.7%$0.00
Next Q-$1.40-$1.57–-$1.21-1.0%$1.4M
Current FY-$5.50-$6.37–-$4.69-0.5%$10.7M
Next FY-$4.02-$5.49–-$2.84+2.8%$181.0M

Short side

FINRA· Jul 15, 2026
715,798
shares short
-75.4%
vs prior settlement
1.0
days to cover
≈0.9%
of shares outstanding
Trading halts
Jul 14, 2026DeletionResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 28, 2026 Earnings calendar
NUVL Q3 2026 Earnings Scheduled · 2026-10-28
Jul 27, 2026 SEC
Nuvalent filed a Form 15-12G to terminate its SEC registration under Section 12(g) following the completion of GSK…
15-12G · Impact 3/10
Jul 22, 2026 Event
JIDEYTRO
Original Approval, Type 1 - New Molecular Entity, TABLET
Jul 15, 2026 SEC
Nasdaq filed a 25-NSE notification to delist Nuvalent, Inc. shares following the completion of GSK plc's acquisition…
25-NSE · Impact 3/10
Jul 15, 2026 SEC
GSK plc has completed its acquisition of Nuvalent, Inc. via a tender offer and merger. The tender offer expired with…
8-K · Impact 5/10
Jul 15, 2026 Insider
Srivastava Sapna disposed of 5,146 shares
Director @ $124.00 ($638.1K)
Jul 15, 2026 Insider
Srivastava Sapna disposed of 3,444 shares
Director
Jul 15, 2026 Insider
Srivastava Sapna disposed of 68,500 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

18 filings · 4 bullish · 4 bearish · 10 neutral
All NUVL filing & press-release reports (18)